Studies on the Nature of Antihemophilic Factor (Factor VIII) FURTHER A B S T R A C T Normal human antihemophilic factor (AHF, factor VIII) and the protein antigenically related to it in hemophilic plasma both appeared in the void volume of columns of agarose (Sepharose 4B) during purification of these agents. On ultracentrifugation upon sucrose gradients, both agents had sedimentation characteristics similar to those of an S30 marker. After reduction, the polypeptide chains of purified normal AHF and of the nonfunctional agent from hemophilic patients had an apparent molecular weight of 200,000 as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. These observations suggest that AHF, purified as described, exists as a large molecule with subunits of molecular weight of approximately 200,000.
Antisera to normal AHF and the nonfunctional agent from hemophilic plasma appeared to be directed against antigens of similar electrophoretic mobility and precipitating characteristics, present in normal and hemophilic plasma but deficient in severe von Willebrand's disease plasma. Both antisera neutralized the AHF clot-promoting activity present in normal plasma, and this property was removed by absorption of the antisera with concentrates of normal or hemophilic plasma but to a greatly reduced extent by concentrates of von Willebrand's disease plasma. These findings suggest that the antigen detected in normal plasma by the antisera appears on a molecule participating in the AHF clotpromoting reaction.
INTRODUCTION
Classic hemophilia is characterized by the functional deficiency in the plasma of an agent participating in the intrinsic pathway of blood coagulation, antihemophilic factor (AHF, factor VIII). Recent studies, employing an antiserum raised in rabbits to highly purified preparations of normal human AHF, have indicated that the plasma of hemophilic subjects contains normal or increased quantities of an antigen precipitating with this antiserum, whereas that of patients with von Willebrand's disease has quantities of this antigen reduced in proportion to the reduction of AHF clot-promoting activity (1) (2) (3) (4) (5) . The antisera used in our earlier studies had the following characteristics: on immunodiffusion they produced a line of identity between hemophilic and normal plasma or purified AHF prepared from normal plasma; on immunoelectrophoresis they produced single precipitin lines of similar mobility with concentrates of normal or hemophilic plasma, and they inhibited the clot-promoting activity of normal plasma in specific assays of AHF activity. Absorption with a fraction rich in AHF prepared from normal plasma or a similar fraction prepared from hemophilic plasma neutralized the inhibitory properties of the antiserum against specific AHF clot-promoting activity (1) .
These earlier studies suggest strongly that the precipitin in the antiserum is directed against the AHF molecule itself and that patients with classic hemophilia produce a functionally incompetent but antigenically normal form of AHF. Conceivably, this incompetent AHF is an aberrant form of the molecule or a precursor of the active form of AHF, with which it shares an antigenic site. Alternately, it could be argued that the precipitin detects a molecule distinct from AHF but in- 
METHODS
The techniques used for the preparation of human plasma, crude ethanol concentrates of AHF, purified normal AHF, absorbed antibody against purified AHF, and pooled normal human plasma and for the assay of functional AHF activity have been described (1) .
Purification of the nonfunctional antigenic protein from the plasma of individual patients with severe classic hemophilia containing no detectable functional AHF was performed by applying the same techniques to hemophilic plasma that were employed to prepared highly purified normal AHF from normal plasma. At -3'C, sufficient 53.3%o ethanol was added to approximately 120-ml samples of hemophilic plasma to bring the final concentration of ethanol to 3%. The mixture was stirred for 30 min at -3'C, and the precipitate was separated at 16,000 g for 10 min at 0°C. The supernatant fluid was discarded, and the precipitate was dissolved in 25 ml imidazole-saline buffer (0.02 M imidazole, 0.14 M NaCl, pH 6.5) at room temperature. 25 ml of 20% (wt/vol) polyethylene glycol (polyethylene glycol 6,000, average molecular weight 6,000-7,500; Matheson, Coleman & Bell, East Rutherford, N. J.) in imidazole-saline buffer was added at room temperature. The mixture was divided into four aliquots, and the precipitate was separated at 12,000 g for 10 min. Each precipitate was washed by suspending in 5 ml of cold 6% ethanol and recentrifuged at room temperature, and the supernatant fluid was discarded. Each precipitate was then dissolved in 2.0 ml imidazole-saline buffer at room temperature with gentle stirring, and the aliquots were combined and resedimented at room temperature for 10 min to remove any remaining particulate material. The dissolved precipitates were pooled, and this concentrate was then applied to a 5.0 X 38 cm column of Sepharose 4B at room temperature and eluted with imidazole-saline buffer at room temperature, employing upward flow. The efflueint was collected in 5.0 ml aliquots. Each fraction was assayed for AHF-life clot-promoting activity and for AHF-like antigen. The contents of tubes with highest amounts of antigen were pooled and concentrated to 2.0 ml by pressure dialysis in an Amicon 8MC Micro-ultrafiltration system (Amicon Corp., Lexington, Mass.) using an Amicon PM30 Diaflo membrane. These concentrated preparations contained approximately 0.2 mg protein/ml. Glycine stabilization of the purified materials was Inot employed in this study.
Antiserum to purified normal AHF or to the material purified from one hemonphilic plasma was raised in 'New Zealand white female rabbits, and the antiserum was collected as previously described (1) . Antiserum to normal AHF was rendered monospecific by absorption with an AHF-poor fraction of normal plasma prepared as previously described (1) . The antiserum to hemophilic material was absorbed with a fraction prepared similarly from hemophilic plasma. To remove all procoagulant activity from antisera used in clotting studies these were then incubated at 60'C for 60 min, and, after cooling to room temperature, 10 mg tricalcium phosphate was added to each ml antiserum, the mixture was agitated for 10 min at room temperature and the serum was separated by centrifugation.
Agarose gels for immunoelectrophoresis and immunodiffusion wN-ere prepared as previously described (1) . Immunoelectrophoresis was performed on ethanol concentrates using a constant potential of 200 V for 90 min at room temperature but otherwise were as previously described, as were immunodiffusion studies.
Quantitative imnmunoelectrophoresis of AHF was carried out as previously described (1) in agarose gels each containing 0.05 ml of antiserum to purified normal AHF; crude ethanol concentrates were not employed in this study.
1O-4L aliquots of the fractions eluted from the columns were applied directly to the wells in the agarose gels; standard curves were made by applying whole plasma in serial dilutions to the wells.
The influence of the antisera on normal AHF was assessed by incubating the antisera with equal volumes of pooled normal human plasma as a source of AHF for 2 h at 37'C and assaying residual AHF activity in the clotpromoting assay. Controls comprised pooled normal plasma incubated with normal rabbit serum, and a control curve was prepared by appropriate dilution of this incubationi mixture. On seven separate occasions, this method assessed the inhibitorv activity of one antiserum as consistently over 83% inhibition, of a second antiserum as consistently between 50 and 70% inhibition, and on three separate occasions that of a third antiserum as between 50 and 60% inihibition of the control.
Protein concentration w as determined by the method of Low-ry, Rosebrough, Farr, and Randall (6) .
Tests for blocking of the activity of the antisera were performed w-ith concentrates of plasma. Ethanol concentrates were prepared as previously described (1) moved by centrifuging, and the supernatant fluids were stored overnight at 4°C. 0.4 ml of each supernatant fraction was mixed with 0.05 ml of pooled normal plasma as a source of AHF and incubated for 2 h at 37°C. 0.55 ml barbital-saline buffer was then added to each mixture, and residual AHF activity was measured without further dilution. AHF activity was compared with that of 0.05 ml pooled normal plasma to hold barbital-saline buffer was added in place of antiserum; standard curves were prepared from these control mixtures, and the amount of inhibition produced by the antiserum absorbed with the various plasma concentrates was estimated by interpolation and compared with that produced by antiserum to which no plasma concentrate had been added. This method ir. our hands has demonstrated that von Willebrand's disease plasma is less efficient than is normal or hemophilic plasma at blocking arntisera to normal human AHF (1) . We have also shown that crude correspondence exists between quantities of AHF detected by clot-promoting or immunoelectrophoresis and this antibody-blocking technique (7) .
Purified preparations of AHF from three normal individuals and of the material produced by two patients with hemophilia were subjected to ultracentrifugation by applying 0.3 ml samples to the surface of 5-20%o sucrose gradients in cellulose nitrate cups (Beckman Instruments, Inc., Palo Alto, Calif.) as previously described (8 
RESULTS
The peaks of AHF-like clot-promoting activity and of AHF-like antigen separated from concentrates of normal plasma were eluted at the same volume from col- umns of Sepharose 4B (Fig. 1) . Antigenic material from the plasma concentrates of patients with classic hemophilia, detected by quantitative immunoelectrophoresis using antiserum to purified normal AHF, eluted at the same point from the same column (Fig. 2) , that is, in the void volume of the column. These results were regularly repeated with normal plasma and were obtained with plasmas from three separate hemophilic patients. Clot-promoting activity was not detected in fractions from runs using hemophilic material. In other experiments, not illustrated, whole plasma samples, rather than ethanol-polyethylene-glycol concentrates of plasma, were applied to a much smaller column (0.9 X 28 cm); under these conditions, too, the antigenic material from hemophilic plasma and the antigenic and clot-promoting agent from normal plasma were eluted in the void volume of the column.
After ultracentrifugation on sucrose density gradients, purified normal AHF activity was found to be maximal in fractions comparable to those in which 30S subribosomal particles were concentrated. 'Maximal AHF clotpromoting activity coincided with maximal concentrationi of AHF-like antigen. This result was reproduced 3 times with AHF prepared from a different normal donor oIn each occasion. In runs concurrent w-ith these. the alntigenic proteins prepared from the plasmas of tw-o hemophilic patients were both concentrate(d in the same fractions as was the antigenic and clot-promoting agent puirified from normal plasma (Fig. 3) . C and E, immunized with normal AHF, had received several boosting doses of the protein, and the antisera from these animals were more powerful inhibitors of AHF clot-promoting activity.
Concentrates of both normal and hemophilic plasma neutralized the ability of the antisera to inhibit the AHF clot-promoting activity of normal plasma to similar degrees, while concentrates of the plasma of a patient with severe von Willebrand's disease (AHF level 0.1 U/ml) exerted a blocking effect approximately equivalent to only one-fifth of its volume of normal plasma (Table II) .
Lines of identity appeared between normal and hemophilic plasma when tested against the antiserum to the hemophilic material (Fig. 5) . No precipitin line appeared opposite the well containing a concentrate prepared from plasma of the patient with severe von Willebrand's disease.
The antiserum to the hemophilic material detected antigens with similar mobility in concentrates of normal and hemophilic plasma (Fig. 6a) . The antigen detected by this antiserum had identical electrophoretic mobility to the antigen detected by the antiserum against purified normal AHF (Fig. 6b ).
DISCUSSION
The gel filtration studies described indicate that the molecules detected in several normal and hemophilic plasmas by the rabbit antiserum to purified normal AHF have a similar minimal molecular size. They both were found in the void volume of columns of Sepharose 4B when unaltered plasma or concentrates of material pre- pared by ethanol and polyethylene glycol precipitation of plasma were applied. Thus the hemophilic material has a similar minimal miiolectilar w-eighlt to that previ- Earlier, the same group had estimated the molecular weight of the reduced fragments as approximately 300,-000, and similar subunits prepared from hemophilic plasma had approximately the same molecular weight (11 
